Last checked at 16 Mar 2020 13:10
Hardman & Co Research Hardman & Co Research: Q&A with Mike Foster on Primary Health Properties (PHP): Final results show accelerating rental growth 16-March-2020 / 13:10 GMT/BST Hardman & Co Research: Final results show accelerating rental growth Primary Health Properties (PHP) is the topic of conversation when Mike Foster, Analyst at Hardman & Co joins DirectorsTalk. We discuss the importance of Ireland and MedicX, the effect of the current global health crisis, dividends, raised estimates for dividend growth and Mike provides a summary of the risks to investors. Please click on the link below to listen to the interview: https://www.hardmanandco.com/research/corporate-research/final-results-show-accelerating-rental-growth/ If you are interested in meeting the company, you can register your interest by clicking on the above link
Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement. About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement. |
998147 16-March-2020
corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.